Patterns of cannabis use among patients with multiple sclerosis
Abstract
To estimate the patterns and prevalence of cannabis use among patients with multiple sclerosis (MS), 220 patients were surveyed in Halifax, Nova Scotia. Seventy-two subjects (36%) reported ever having used cannabis for any purpose; 29 respondents (14%) reported continuing use of cannabis for symptom treatment. Medical cannabis use was associated with male gender, tobacco use, and recreational cannabis use. The symptoms reported by medical cannabis users to be most effectively relieved were stress, sleep, mood, stiffness/spasm, and pain.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press, 1986: 1–19.
2.
Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci. 2003; 30: 201–205.
3.
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997; 38: 44–48.
4.
Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003; 102: 211–216.
5.
Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987; 7: 39–50.
6.
Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 236: 120–122.
7.
Dell’Osso LF. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology. 2000; 54: 2190–2191.
8.
Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55: 324–328.
9.
Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002; 58: 1404–1407.
10.
Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362: 1517–1526.
Information & Authors
Information
Published In
Copyright
© 2004.
Publication History
Received: November 11, 2003
Accepted: March 2, 2004
Published online: June 7, 2004
Published in print: June 8, 2004
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- The Development of Cannabinoids as Therapeutic Agents in the United States, Pharmacological Reviews, 76, 5, (915-955), (2024).https://doi.org/10.1124/pharmrev.123.001121
- Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions, Cannabis and Cannabinoid Research, 9, 2, (669-687), (2024).https://doi.org/10.1089/can.2021.0156
- Symptom severity is a major determinant of cannabis‐based products use among people with multiple sclerosis, Journal of Clinical Nursing, 32, 17-18, (6460-6473), (2023).https://doi.org/10.1111/jocn.16674
- Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational study, Multiple Sclerosis and Related Disorders, 75, (104742), (2023).https://doi.org/10.1016/j.msard.2023.104742
- Cannabis Use: A New Risk Behaviour Among Adults With Congenital Heart Disease, CJC Pediatric and Congenital Heart Disease, 2, 6, (484-489), (2023).https://doi.org/10.1016/j.cjcpc.2023.09.001
- The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis, Neurobiology and Physiology of the Endocannabinoid System, (229-240), (2023).https://doi.org/10.1016/B978-0-323-90877-1.00025-5
- Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases, BioFactors, 49, 3, (560-583), (2023).https://doi.org/10.1002/biof.1936
- Medical cannabis use in Canadians with multiple sclerosis, Multiple Sclerosis and Related Disorders, 59, (103638), (2022).https://doi.org/10.1016/j.msard.2022.103638
- Cannabis Use and Sleep, Handbook of Substance Misuse and Addictions, (1369-1398), (2022).https://doi.org/10.1007/978-3-030-92392-1_70
- Cannabis Use and Sleep, Handbook of Substance Misuse and Addictions, (1-30), (2022).https://doi.org/10.1007/978-3-030-67928-6_70-1
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.